← All trials
NCT05587283
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- May 31, 2023
- First posted
- Oct 20, 2022
- Last posted
- Oct 27, 2022
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AtoGen Co. LtdLead sponsor
- Southern Star Research Pty Ltd.Collaborator
- Scientia Clinical Research Limited SydneyOverall official - principal investigator
- ATOGEN AUSTRALIA PTY LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.